When we compared the myocarditis patients (n = 35) versus non‐myocarditis patients (n = 9) (Table 2), they presented higher cTnI levels (median of 25.1‐fold the upper limit vs. 0.27‐fold, p < 0.001), higher CK levels (median of 6‐fold the upper limit vs. 0.3‐fold, p = 0.003), higher CK‐MB levels (median of 4.9‐fold the upper limit vs. 0.7‐fold, p = 0.013), and shorter time to the incidence of adverse cardiovascular events (median of 41 days vs. median of 115 days, p = 0.022) after ICI treatment (Figure 1). This evidence concerns the gene TNNI3 and myocarditis.